- Home
- SDRL vs NRIX Comparison
SDRL vs NRIX Comparison
Compare SDRL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDRL | NRIX |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SDRL | NRIX |
|---|---|---|
| Price | $45.11 | $23.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $56.00 | $30.50 |
| AVG Volume (30 Days) | 878.7K | ★ 1.6M |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,437,000,000.00 | $76,987,000.00 |
| Revenue This Year | $5.22 | N/A |
| Revenue Next Year | $16.68 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.75 | ★ 99.31 |
| 52 Week Low | $27.40 | $8.20 |
| 52 Week High | $55.47 | $25.09 |
Technical Indicators
Market Signals| Indicator | SDRL | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 58.98 |
| Support Level | $44.59 | $14.63 |
| Resistance Level | $45.32 | $24.98 |
| Average True Range (ATR) | 1.36 | 1.21 |
| MACD | 0.76 | -0.26 |
| Stochastic Oscillator | 91.53 | 52.40 |
Price Performance
Historical ComparisonAbout SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, and others. The company derives maximum revenue from Brazil.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.